3
Announcements
Trials
Browse
Landscape
Phase
Phase NA
1
Status
Unknown
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gynecologic
1
Conditions
Urogenital Neoplasms
1
Ovarian Neoplasms
1
Ovarian Diseases
1
Ovarian Cysts
1
Neoplasms
1
Gonadal Disorders
1
Genital Neoplasms, Female
1
Genital Diseases, Female
1
Endocrine System Diseases
1
Endocrine Gland Neoplasms
1
Disease
1
Cysts
1
Adnexal Diseases
1
Interventions
pembrolizumab
5
padeliporfin
5
Nivolumab
5
fludarabine
4
aldesleukin
4
Ipilimumab
4
Cyclophosphamide
4
atezolizumab
3
Specimen Handling
3
Paclitaxel
3
Magnetic Resonance Spectroscopy
3
Gemcitabine
3
Carboplatin
3
vedolizumab
2
olaparib
2
niraparib
2
motexafin gadolinium
2
cabozantinib
2
anlotinib
2
abiraterone
2
Therapeutics
2
Sunitinib
2
Standard of Care
2
Riluzole
2
Radiation Dose Hypofractionation
2
Prednisone
2
Pluvicto
2
Mitomycin
2
LDP-02
2
Infliximab
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Interventional
×
Urogenital Neoplasms
×
Diffusion
×
Clear all
NCT02836275
2020-04-14
IOTA-MRI
KU Leuven
Phase NA
Unknown
250 enrolled